Impact of Fibroblast Growth Factor-23 on Peripheral Arterial Disease in Type 2 Diabetes Mellitus: A Comparative Cross-Sectional Pilot Study
- Resource Type
- Authors
- Nurgul Ozgur; Esra Hatipoglu; Hasan Ilkova; Serkan Feyyaz Yalin; Zeynep Oşar Siva; Atilla Süleyman Dikici; Mutlu Niyazoglu; Özlem Balcı Ekmekci
- Source
- Turkish Journal of Endocrinology and Metabolism, Vol 19, Iss 4, Pp 119-123 (2015)
- Subject
- Fibroblast growth factor 23
medicine.medical_specialty
Arterial disease
Endocrinology, Diabetes and Metabolism
Gastroenterology
lcsh:Diseases of the endocrine glands. Clinical endocrinology
Pathogenesis
Diabetic nephropathy
Diabetes mellitus
peripheral arterial disease
Internal medicine
Internal Medicine
medicine
lcsh:RC648-665
business.industry
arterial calcification
Type 2 Diabetes Mellitus
medicine.disease
Peripheral
Endocrinology
nephropathy
fibroblast growth factor-23
atherosclerosis
business
Kidney disease
- Language
- English
- ISSN
- 1301-2193
Purpose: To evaluate whether fibroblast growth factor-23 (FGF-23) has a common role in the pathogenesis of peripheral arterial disease (PAD) and chronic kidney disease (CKD) in type-2 diabetes mellitus (DM). Material and Method: Twenty-one patients with diabetic nephropathy composed the diabetic nephropathy (DM-NP) group and 20 subjects with DM but without NP constituted the DM group. The control group was comprised of 10 age- and gender-matched non-diabetic individuals with CKD. Results: FGF-23 levels were similar in DM-NP and CKD groups (p=0.5). Both groups had higher FGF-23 levels compared to DM group (p